Antonella Dal Cin

Mrs. Antonella Dal Cin


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2024 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
FGFabiola Giudici
Fabiola Giudici
APAngela De Paoli
Angela De Paoli
FTFederica Toffolutti
Federica Toffolutti
SGStefano Guzzinati
Stefano Guzzinati
SFSilvia Francisci
Silvia Francisci
RBRoberta Bosu
Roberta Bosu
This study aims to estimate long-term survival, cancer prevalence, and several cure indicators for Italian women with gynecological cancers. Thirty-one cancer registries, representing 47% of the Italian female population, were included. Mixture cure models were used to estimate net survival, cure fraction, time to cure (when 5-year conditional net survival becomes > 95%), cure prevalence (women who will not die of cancer), and already cured (living longer than time to cure). In 2018, 0.4% (121 704) of Italian women were alive after diagnosis of corpus uteri cancer, 0.2% (52 551) after cervical cancer, and 0.2% (52 153) after ovarian cancer. More than 90% of patients with uterine cancers and 83% with ovarian cancer will not die from their neoplasm (cure prevalence). Women with gynecological cancers have a residual excess risk of death <5% at 5 years after diagnosis. The cure fraction was 69% for corpus uteri, 32% for ovarian, and 58% for cervical cancer patients. Time to cure was ≤10 years for women with gynecological cancers aged <55 years; 74% of patients with cervical cancer, 63% with corpus uteri cancer, and 55% with ovarian cancer were already cured. These results can contribute to improving follow-up programs for women with gynecological cancers and supporting efforts against discrimination of already cured ones. This article is part of a Special Collection on Gynecological Cancers.

16 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
EFEliana Ferroni
Eliana Ferroni
AAAlessandra Andreotti
Alessandra Andreotti
SGStefano Guzzinati
Stefano Guzzinati
SBSusanna Baracco
Susanna Baracco
MBMaddalena Baracco
Maddalena Baracco
MZManuel Zorzi
Manuel Zorzi
Background: Population-level evidence on delivery of neuro-oncology care is essential for evaluating access, equity, and quality of treatment pathways. However, real-world data describing how patients with central nervous system (CNS) tumors, especially with glioblastoma, are managed across healthcare systems remain limited. This study aimed to characterize treatment pathways using linked registry and administrative data within a regional care network. Methods: All adult CNS tumors diagnosed between 2016 and 2020 were identified in the Veneto Cancer Registry. Tumor grading was derived using a validated text-mining algorithm, and surgical, radiotherapy, and systemic treatments were captured through linkage with regional healthcare utilization databases. Patterns of care were evaluated by tumor subtype, grade, and diagnostic pathway. Results: Among 1,634 histologically confirmed tumors, glioblastoma represented the largest group. Surgical intervention was widely implemented, with high resection rates in glioblastoma and meningioma. Combined chemoradiotherapy constituted the primary adjuvant approach for glioblastoma and high-grade diffuse gliomas, whereas management of lower-grade tumors showed greater variability. Approximately one third of patients received no oncologic therapy, primarily associated with older age or diagnostic uncertainty. Analysis of recurrent glioblastoma showed heterogeneous systemic treatment use, reflecting evolving therapeutic practice. Conclusions: Linking population-based registry and administrative data provides actionable insight into real-world delivery of neuro-oncology care, in particular for glioblastoma patients. This approach enables monitoring of treatment variability, identification of potential access gaps, and evaluation of system-level performance, supporting data-driven planning of multidisciplinary services and future quality improvement initiatives.

21 April 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
EFEliana Ferroni
Eliana Ferroni
AAAlessandra Andreotti
Alessandra Andreotti
SGStefano Guzzinati
Stefano Guzzinati
SBSusanna Baracco
Susanna Baracco
MBMaddalena Baracco
Maddalena Baracco
MZManuel Zorzi
Manuel Zorzi
Background: Population-level evidence on delivery of neuro-oncology care is essential for evaluating access, equity, and quality of treatment pathways. However, real-world data describing how patients with central nervous system (CNS) tumors, especially with glioblastoma, are managed across healthcare systems remain limited. This study aimed to characterize treatment pathways using linked registry and administrative data within a regional care network. Methods: All adult CNS tumors diagnosed between 2016 and 2020 were identified in the Veneto Cancer Registry. Tumor grading was derived using a validated text-mining algorithm, and surgical, radiotherapy, and systemic treatments were captured through linkage with regional healthcare utilization databases. Patterns of care were evaluated by tumor subtype, grade, and diagnostic pathway. Results: Among 1634 histologically confirmed tumors, glioblastoma represented the largest group. Surgical intervention was widely implemented, with high resection rates in glioblastoma and meningioma. Combined chemoradiotherapy constituted the primary adjuvant approach for glioblastoma and high-grade diffuse gliomas, whereas management of lower-grade tumors showed greater variability. Approximately one-third of patients received no oncologic therapy, primarily associated with older age or diagnostic uncertainty. Analysis of recurrent glioblastoma showed heterogeneous systemic treatment use, reflecting evolving therapeutic practice. Conclusions: Linking population-based registry and administrative data provides actionable insight into real-world delivery of neuro-oncology care, in particular for glioblastoma patients. This approach enables monitoring of treatment variability, identification of potential access gaps, and evaluation of system-level performance, supporting data-driven planning of multidisciplinary services and future quality improvement initiatives.